Mark M. Awad

2004–2025 年に発表

194
論文数
33,299
被引用数
88
h 指数
180
i10 指数

被引用数

Mark M. Awad の年別被引用数1971 年: 被引用 3 件1976 年: 被引用 2 件2001 年: 被引用 2 件2004 年: 被引用 2 件2005 年: 被引用 8 件2006 年: 被引用 14 件2007 年: 被引用 10 件2008 年: 被引用 10 件2009 年: 被引用 23 件2010 年: 被引用 19 件2011 年: 被引用 24 件2012 年: 被引用 8 件2013 年: 被引用 27 件2014 年: 被引用 64 件2015 年: 被引用 116 件2016 年: 被引用 161 件2017 年: 被引用 215 件2018 年: 被引用 338 件2019 年: 被引用 1,080 件2020 年: 被引用 1,741 件2021 年: 被引用 1,939 件2022 年: 被引用 1,760 件2023 年: 被引用 1,712 件2024 年: 被引用 2,774 件2025 年: 被引用 1,718 件2026 年: 被引用 53 件1972〜1975 年は被引用が無いため表示していません1977〜2000 年は被引用が無いため表示していません2002〜2003 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,267 件、この内訳の 25.3%中国: 引用元論文 2,977 件、この内訳の 17.6%イタリア: 引用元論文 949 件、この内訳の 5.6%イギリス: 引用元論文 823 件、この内訳の 4.9%フランス: 引用元論文 740 件、この内訳の 4.4%日本: 引用元論文 714 件、この内訳の 4.2%ドイツ: 引用元論文 650 件、この内訳の 3.9%スペイン: 引用元論文 595 件、この内訳の 3.5%カナダ: 引用元論文 459 件、この内訳の 2.7%スイス: 引用元論文 410 件、この内訳の 2.4%オランダ: 引用元論文 395 件、この内訳の 2.4%韓国: 引用元論文 374 件、この内訳の 2.2%
0%25.3%その他 20.9%

分野

  • Medicine70.7%
  • Biochemistry, Genetics and Molecular Biology20.3%
  • Immunology and Microbiology5.3%
  • Computer Science1.3%
  • Engineering0.7%
  • Neuroscience0.5%
  • その他1.2%

トピック

  • Cancer Immunotherapy and Biomarkers14.3%
  • Lung Cancer Treatments and Mutations10.1%
  • Lung Cancer Research Studies6.3%
  • Cancer Genomics and Diagnostics4.5%
  • Lung Cancer Diagnosis and Treatment3.9%
  • Immunotherapy and Immune Responses3.7%
  • その他57.2%

共著者

全論文

検索で開く
  1. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2022 被引用: 2,558

  2. Acquired Resistance to KRAS G12C Inhibition in Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , J. David Lawson, Peter Olson, Piro Lito, Sai-Hong I. Ou, James G. Christensen, Pasi A. Jänne, Andrew J. Aguirre - New England Journal of Medicine 2021 被引用: 1,164

  3. STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brett W. Carter, Jeremy Erasmus, Darragh Halpenny, Andrew J. Plodkowski, Niamh M. Long, Mizuki Nishino, Warren L. Denning, Ana Galán‐Cobo, Haïfa Hamdi, Taghreed Hirz, Pan Tong, Jing Wang, Jaime Rodriguez‐Canales, Pamela Villalobos, Edwin R. Parra, Neda Kalhor, Lynette M. Sholl, Jennifer L. Sauter, Achim A. Jungbluth, Mari Mino–Kenudson, Roxana Azimi, Yasir Y. Elamin, Jianjun Zhang, Giulia C. Leonardi, Fei Jiang, Kwok‐Kin Wong, J. Jack Lee, Vassiliki A. Papadimitrakopoulou, Ignacio I. Wistuba, Vincent A. Miller, Garrett M. Frampton, Jedd D. Wolchok, Alice T. Shaw, Pasi A. Jänne, Philip J. Stephens, Charles M. Rudin, William J. Geese, Lee A. Albacker, John V. Heymach - Cancer Discovery 2018 被引用: 1,604

  4. A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Melissa A. Moles, Kelledy Manson, Joel Greshock, Zakaria Khondker, Ed Fritsch, Michael S. Rooney, Mark DeMario, Richard B. Gaynor, Lakshmi Srinivasan - Cell 2020 被引用: 763

  5. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , - Cancer Cell 2022 被引用: 222

  6. Perioperative Nivolumab in Resectable Lung Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 被引用: 447

  7. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Justin F. Gainor, Matthew D. Hellmann, Mark M. Awad - Journal of Thoracic Oncology 2021 被引用: 367

  8. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

    著者: , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 759

  9. Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rameen Beroukhim, Pratiti Bandopadhayay, Mark M. Awad, Prafulla C. Gokhale, Paul T. Kirschmeier, Jarrod A. Marto, Fernando D. Camargo, Rizwan Haq, Cloud P. Paweletz, Kwok‐Kin Wong, David A. Barbie, Henry W. Long, Nathanael S. Gray, Pasi A. Jänne - Cancer Cell 2020 被引用: 472

  10. Federated benchmarking of medical artificial intelligence with MedPerf

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor Bittorf, Sreekar Reddy Puchala, Biagio Ricciuti, Soujanya Samineni, Eshna Sengupta, Akshay Chaudhari, Cody Coleman, Bala Desinghu, Gregory F. Diamos, Debo Dutta, Diane Feddema, Grigori Fursin, Xinyuan Huang, Satyananda Kashyap, Nicholas D. Lane, Indranil Mallick, Pietro Mascagni, Virendra Mehta, Cassiano Ferro Moraes, Vivek Natarajan, Nikola Nikolov, Nicolas Padoy, Gennady Pekhimenko, Vijay Janapa Reddi, G. Anthony Reina, Pablo Ribalta, Abhishek Singh, Jayaraman J. Thiagarajan, Jacob Albrecht, Thomas Wolf, Geralyn Miller, Huazhu Fu, Prashant Shah, Daguang Xu, Poonam Yadav, David Talby, Mark M. Awad, Jeremy P. Howard, Michael Rosenthal, Luigi Marchionni, Massimo Loda, Jason M. Johnson, Spyridon Bakas, Peter Mattson - Nature Machine Intelligence, Nat. Mac. Intell. 2023 被引用: 149

  11. Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Eliezer M. Van Allen, Mizuki Nishino, Lynette M. Sholl, David C. Christiani, Xihong Lin, Scott J. Rodig, Matthew D. Hellmann, Mark M. Awad - JAMA Oncology 2022 被引用: 384

  12. STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Glenn Dranoff, Peter S. Hammerman, Kwok‐Kin Wong - Cancer Research 2016 被引用: 630

  13. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jing Wang, Blerina Resuli, Lorenza Landi, Shu-Chi Tseng, Mizuki Nishino, Subba R. Digumarthy, Waree Rinsurongkawong, Vadeerat Rinsurongkawong, Ara A. Vaporciyan, George R. Blumenschein, Jianjun Zhang, Dwight H. Owen, Collin M. Blakely, Giannis Mountzios, Catherine A. Shu, Christine M. Bestvina, Marina Chiara Garassino, Kristen A. Marrone, Jhanelle E. Gray, Sandip Pravin Patel, Amy L. Cummings, Heather A. Wakelee, Juergen Wolf, Giorgio V. Scagliotti, Federico Cappuzzo, Fabrice Barlési, Pradnya D. Patil, Leylah Drusbosky, Don L. Gibbons, Funda Meric‐Bernstam, J. Jack Lee, John V. Heymach, David S. Hong, Rebecca S. Heist, Mark M. Awad, Ferdinandos Skoulidis - Cancer Discovery 2023 被引用: 181

  14. Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial

    著者: , , , , , , , , , , , , , , , - The Lancet Oncology 2020 被引用: 640

  15. Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Xitao Wang, Bowen Chen, Fangxin Hong, Lynette M. Sholl, Michael Tolstorukov, Kathleen L. Pfaff, Pasi A. Jänne, Evisa Gjini, Robin Edwards, Scott J. Rodig, Ellis L. Reinherz, Matthew G. Oser, David A. Barbie - Cancer Discovery 2021 被引用: 214

  16. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brian S. Henick, Naiyer A. Rizvi, Pasi A. Jänne, Mark M. Awad, Andrew Chow, Benjamin D. Greenbaum, Marta Łuksza, Alice T. Shaw, Jedd D. Wolchok, Nir Hacohen, Gad Getz, Justin F. Gainor - Nature Genetics 2023 被引用: 186

  17. Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

    著者: , , , , , , , , , , , , , , , - Cancer Cell 2018 被引用: 894

  18. First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 596

  19. Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raymond H. Mak, Mark M. Awad, Scott J. Rodig, Helen X Chen, Catherine J. Wu, Arta M. Monjazeb, F. Stephen Hodi - The Lancet Oncology 2022 被引用: 232

  20. LBA1 CheckMate 77T: Phase III study comparing neoadjuvant nivolumab (NIVO) plus chemotherapy (chemo) vs neoadjuvant placebo plus chemo followed by surgery and adjuvant NIVO or placebo for previously untreated, resectable stage II–IIIb NSCLC

    著者: , , , , , , , , , , , , , , , , , , - Annals of Oncology 2023 被引用: 100

  21. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2016 被引用: 1,392

  22. MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

    著者: , , , , , , , , , , , , - Journal of Clinical Oncology 2016 被引用: 688

  23. TargetingMETDysregulation in Cancer

    著者: , , , - Cancer Discovery 2020 被引用: 222

  24. Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

    著者: , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 被引用: 336